Loading...
•
Dec 31, 2021
Royalty Pharma Q4 2021 Earnings Report
Reported financial results for Q4 and full year 2021, and introduced 2022 Adjusted Cash Receipts guidance.
Key Takeaways
Royalty Pharma reported strong Q4 and full year 2021 results, with Adjusted Cash Receipts growing by 12% in Q4 and 18% for the full year. The company also announced transactions of $3.0 billion in 2021 and introduced 2022 Adjusted Cash Receipts guidance of $2,225 to $2,300 million.
Net cash provided by operating activities (GAAP) was $490 million.
Adjusted Cash Receipts (non-GAAP) reached $543 million.
Adjusted Cash Flow (non-GAAP) was $488 million.
Announced transactions of up to $3.0 billion in 2021, including $2.3 billion in upfront payments.
Revenue by Segment
Forward Guidance
Royalty Pharma expects 2022 Adjusted Cash Receipts to be between $2,225 million and $2,300 million, excluding new transactions announced after the date of this release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...